Navigation Links
Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Elementâ„¢ Stent
Date:9/21/2010

NATICK, Mass., Sept. 21 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent.  The results provided 30-day and nine-month clinical outcomes and nine-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the PROMUS Element Stent.  Analysis of the data was presented by Ian Meredith, M.B.B.S., Ph.D., Director of Cardiology at the Monash Medical Centre in Melbourne, Australia and Principal Investigator of the PLATINUM QCA study, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C.

The PROMUS Element Stent features a novel platinum chromium (PtCr) alloy and innovative stent design, which combine to offer greater radial strength and flexibility while reducing stent recoil.  The stent geometry helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system.  The higher density PtCr alloy provides superior visibility while permitting thinner struts compared to prior-generation stents (1).

"The nine-month angiographic and IVUS data from the PLATINUM QCA study are impressive and show the acute performance advantages of the platinum chromium PROMUS Element Stent," said Prof. Meredith.  "With the same drug and polymer loading and comparable release kinetics as the PROMUS® Stent, the PROMUS Element Stent achieved similar late loss and significantly better stent apposition.  These results give me great confidence in the transferability of the everolimus drug and its proven clinical outcomes, as well as the potential benefits of the new platinum
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014  Vermillion, ... company focused on gynecologic cancers and women,s health, has ... of Sales and Managed Markets. Ms. Bauzon ... traction and expanding payer coverage for laboratory services companies. ... most recently with PerkinElmer, Inc., where she held the ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... INDIANAPOLIS, Nov. 2, 2010 Eli Lilly and Company (NYSE: ... focused on diabetes in China, where the incidence of the disease ... in Shanghai in the second half of 2011, will focus on ... leadership in this disease area and the priority Lilly places on ...
... Back Awards is now accepting nominations to honor individuals ... The Welcome Back Awards , now in its 13th ... to recognize outstanding achievements in the fight against depression and ... Welcome Back Awards continue to motivate healthcare providers ...
Cached Medicine Technology:Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 2Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 3Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 4The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 2The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 3
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... 22, 2014 Paying tuition and other ... the coming year for four nurse educators pursuing advanced ... League for Nursing Foundation for Nursing Education . This ... $28,000, $10,000 more than in 2013, thanks to these ... and Elizabeth Isaac Marcil Endowment Funds, both donated by ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... -- Back-to-school time provides an opportunity for parents to ... schedules, an expert suggests. "Forget New Year,s resolutions; ... be the start of a new fitness and exercise ... at the University of the Sciences in Philadelphia, said ... activities likely to build up, "it,s important for mom ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... Promote Patient Safety for Care Abroad, CHICAGO, ... considering traveling abroad for medical care, new guiding,principles ... American Medical,Association,s (AMA) annual policy-making meeting. The nine ... care abroad for consideration,by patients, employers, insurers and ...
... and ,lack of time, as, the top three factors that ... ... 17 Findings from a survey,released today reveal that the vast ... less than half of those who,consider making lifestyle changes (46%) are ...
... Functioning in Fibromyalgia Patients, INDIANAPOLIS, June ... (FDA) has approved Cymbalta(R) (duloxetine HCl) for ... disorder, Eli Lilly,and Company (NYSE: LLY ... serotonin-,norepinephrine reuptake inhibitor with proven efficacy for ...
... FRANCISCO, June 16 Following a study,indicating that strong ... community, Asian & Pacific Islander Wellness Center has,developed a ... of,stigma in the Chinese community., Joan Chen generously ... for the TalkAIDS campaign, where she asks "Don,t think ...
... 16 The Concerned Shareholders of Biovail,Corporation (NYSE: BVF ... of Biovail Corporation:, , June 16, 2008, William ... Mississauga Road Mississauga, Ontario l5N 8M5, Dear Mr. ... debate between the two of,us either Wednesday or Thursday of ...
... Product Line and International ... ... the leader,in legal holds and retention management solutions, announced it secured ... Lightspeed Venture Partners, Azure Capital, Granite,Ventures, and Cipio Partners, all renewed ...
Cached Medicine News:Health News:AMA Provides First Ever Guidance on Medical Tourism 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 3Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 2Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 3Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 5Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 6Health News:TalkAIDS: A&PI Wellness Center Launches a New Anti-Stigma Campaign With International Star Joan Chen 2Health News:Letter Challenges Biovail CEO to a Debate 2Health News:Letter Challenges Biovail CEO to a Debate 3Health News:PSS Systems Secures $18 Million in Financing 2Health News:PSS Systems Secures $18 Million in Financing 3Health News:PSS Systems Secures $18 Million in Financing 4
... stabilized hyaluronic acid-based dermal filler and ... the U.S. market. It is indicated ... facial wrinkles and folds (such as ... under the skins surface to replenish ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... clinically proven aminophylline directly to the area ... reduction with the aminophylline containing cream has ... increase in the firmness of the thighs. ... skin where it causes the body fat ...
... is a unique, non-invasive way of ... of cellulite and improving overall skin ... was used to rehabilitate scars, burns ... surprising side-affect was discovered - the ...
Medicine Products: